V-ATPase inhibition overcomes trastuzumab resistance in breast cancer

The V-ATPase-Inhibitor Archazolid Abrogates Tumor Metastasis via Inhibition of Endocytic Activation of the Rho-GTPase Rac1

(2012) R. M. Wiedmann et al.   CANCER RESEARCH

Frequent Mutational Activation of the PI3K-AKT Pathway in Trastuzumab-Resistant Breast Cancer

(2012) S. Chandarlapaty et al.   CLINICAL CANCER RESEARCH

The HSP90 inhibitor geldanamycin perturbs endosomal structure and drives recycling ErbB2 and transferrin to modified MVBs/lysosomal compartments

(2012) Katia Cortese et al.   MOLECULAR BIOLOGY OF THE CELL

A human genome-wide screen for regulators of clathrin-coated vesicle formation reveals an unexpected role for the V-ATPase

(2012) Patrycja Kozik et al.   NATURE CELL BIOLOGY

The signaling and transformation potency of the overexpressed HER2 protein is dependent on the normally-expressed EGFR

(2011) Xiangdong Zhou et al.   CELLULAR SIGNALLING

Primary trastuzumab resistance: new tricks for an old drug

(2010) Jason A. Wilken et al.   Annals of the New York Academy of Sciences

Multiple molecular mechanisms underlying trastuzumab and lapatinib resistance in JIMT-1 breast cancer cells

(2010) Katri Köninki et al.   CANCER LETTERS

The vacuolar ATPase is required for physiological as well as pathological activation of the Notch receptor

(2010) T. Vaccari et al.   DEVELOPMENT

Inhibition of macroautophagy by bafilomycin A1 lowers proliferation and induces apoptosis in colon cancer cells

(2009) Ya Chun Wu et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Resistance to Trastuzumab in Breast Cancer

(2009) P. R. Pohlmann et al.   CLINICAL CANCER RESEARCH

Mammalian autophagy: core molecular machinery and signaling regulation

(2009) Zhifen Yang et al.   CURRENT OPINION IN CELL BIOLOGY

Expression of Epidermal Growth Factor Receptor or ErbB3 Facilitates Geldanamycin-Induced Down-Regulation of ErbB2

(2009) N. M. Pedersen et al.   MOLECULAR CANCER RESEARCH

The V-type H+-ATPase in vesicular trafficking: targeting, regulation and function

(2008) Vladimir Marshansky et al.   CURRENT OPINION IN CELL BIOLOGY

Trastuzumab decreases the number of circulating and disseminated tumor cells despite trastuzumab resistance of the primary tumor

(2007) Márk Barok et al.   CANCER LETTERS